FDA Approves TALZENNA-XTANDI Combo for Earlier-Stage Prostate Cancer; Phase 3 Shows 52% Risk Cut
PFE sits 26% above its 52-week low of $23.62.
Summary
The FDA approved the TALZENNA plus XTANDI combination for an earlier metastatic prostate cancer treatment setting, expanding the label into a larger patient population. Supporting Phase 3 TALAPRO-3 data showed a 52% reduction in the risk of progression or death. This is a label expansion for two already-marketed drugs, so it adds revenue potential rather than introducing a new asset. It follows the October 7 FDA approval of TUKYSA maintenance therapy, extending a run of oncology regulatory wins. The incremental revenue is modest against Pfizer's roughly $15B quarterly top line, so the stock impact is likely limited but directionally positive.
At the time of this announcement, PFE was trading at $29.82 on NYSE in the Life Sciences sector, with a market capitalization of approximately $169.9B. The 52-week trading range was $23.62 to $30.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.